Since there is not a single unequivocal marker of inflammation and demyelination at early stages of MS, we think that the determination of TNF and its receptor balance in the CSF could contribute, together with advanced MRI data, to identify patients with a worse prognosis who need more aggressive treatment immediately. The gene discussed is TNF; the disease is myeloid sarcoma.